NCT06189924 Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients
| NCT ID | NCT06189924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic |
| Condition | Acute Respiratory Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-03-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Mechanically ventilated intensive care patients will be sampled for a small amount of exhaled breath condensate from the ventilator circuit and for venous blood. Proteomic analysis of the exhaled breath condensate will be performed using mass spectrometry and in the blood sample, corresponding changes in the DNA, RNA, proteins, and metabolites will be studied. Resulting profiles will be correlated with routinely monitored parameters in order to identify patterns corresponding to various pathologies in order to enable their early detection.
Eligibility Criteria
Inclusion Criteria: Intensive care setting Mechanical ventilation Ventilator/ventilator circuit technically suitable for sampling of exhaled breath condensate Exclusion Criteria: Mechanical ventilation challenging to the extent that the insertion of the sampling kit into the ventilator circuit would substantially increase the risk for respiratory deterioration
Contact & Investigator
Emil Berta, MD PhD
PRINCIPAL INVESTIGATOR
IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry
Frequently Asked Questions
Who can join the NCT06189924 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Respiratory Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06189924 currently recruiting?
Yes, NCT06189924 is actively recruiting participants. Contact the research team at e.berta@upol.cz for enrollment information.
Where is the NCT06189924 trial being conducted?
This trial is being conducted at Olomouc, Czechia, Olomouc, Czechia.
Who is sponsoring the NCT06189924 clinical trial?
NCT06189924 is sponsored by The Institute of Molecular and Translational Medicine, Czech Republic. The principal investigator is Emil Berta, MD PhD at IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry. The trial plans to enroll 200 participants.